Sec Form 4 Filing - ZANTE GREG @ Viking Therapeutics, Inc. - 2023-04-11

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ZANTE GREG 2. Issuer Name and Ticker or Trading Symbol Viking Therapeutics, Inc. [ VKTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Financial Officer (Last) (First) (Middle) C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350 3. Date of Earliest Transaction (MM/DD/YY) 04/11/2023 (Street) SAN DIEGO, CA92121 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $0.00001 per share 04/11/2023 M( 1 ) 3,242 A $ 7.77 152,521 D Common Stock, par value $0.00001 per share 04/11/2023 M( 1 ) 8,500 A $ 4.68 161,021 D Common Stock, par value $0.00001 per share 04/11/2023 M( 1 ) 30,000 A $ 4.88 191,021 D Common Stock, par value $0.00001 per share 04/11/2023 M( 1 ) 14,553 A $ 5.8 205,574 D Common Stock, par value $0.00001 per share 04/11/2023 S( 1 ) 56,295 D $ 18.0037 149,279 D Common Stock, par value $0.00001 per share 04/12/2023 M( 1 ) 37,447 A $ 5.8 186,726 D Common Stock, par value $0.00001 per share 04/12/2023 M( 1 ) 4,097 A $ 7.77 190,823 D Common Stock, par value $0.00001 per share 04/12/2023 S( 1 ) 41,544 D $ 18 149,279 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 7.77 04/11/2023 M( 1 ) 3,242 01/03/2021( 2 ) 01/03/2030 Common Stock 3,242 $ 0 16,847 ( 3 ) D Stock Option (right to buy $ 4.68 04/11/2023 M( 1 ) 8,500 03/31/2021( 2 ) 03/31/2030 Common Stock 8,500 $ 0 8,500 D Stock Option (right to buy $ 4.88 04/11/2023 M( 1 ) 30,000 01/03/2023( 2 ) 01/03/2032 Common Stock 30,000 $ 0 90,000 D Stock Option (right to buy $ 5.8 04/11/2023 M( 1 ) 14,553 01/04/2022( 4 ) 01/04/2031 Common Stock 14,553 $ 0 63,447 D Stock Option (right to buy $ 5.8 04/12/2023 M( 1 ) 37,447 01/04/2022( 4 ) 01/04/2031 Common Stock 37,447 $ 0 26,000 D Stock Option (right to buy) $ 7.77 04/12/2023 M( 1 ) 4,097 01/03/2021( 2 ) 01/03/2030 Common Stock 4,097 $ 0 12,750 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ZANTE GREG C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO, CA92121 Chief Financial Officer Signatures /s/ Michael Morneau as Attorney-in-Fact 04/13/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. ( 2 )25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. ( 3 )The Form 4 filed by the Reporting Person on April 3, 2023 reporting, among other things, the exercise of 30,911 shares subject to this option on April 3, 2023 inadvertently indicated that there were 0 shares remaining subject to this option after such exercise. That Form 4 should have reflected that there were 20,089 shares remaining subject to this option after such exercise and the balance has been adjusted accordingly in this Form 4. ( 4 )One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.